XTX Topco Ltd Invests $313,000 in United Therapeutics Corporation (NASDAQ:UTHR)

XTX Topco Ltd purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,016 shares of the biotechnology company’s stock, valued at approximately $313,000.

Other hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC boosted its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 50 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $49,000. State of Wyoming acquired a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $62,000. Curat Global LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $63,000. Finally, Natixis acquired a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $85,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

UTHR opened at $301.50 on Monday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The company has a market capitalization of $13.60 billion, a P/E ratio of 11.77, a P/E/G ratio of 4.57 and a beta of 0.57. The stock has a fifty day moving average of $296.64 and a 200-day moving average of $310.59.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period in the prior year, the business posted $5.85 EPS. The firm’s quarterly revenue was up 11.7% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent analyst reports. Cantor Fitzgerald initiated coverage on United Therapeutics in a report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price objective for the company. Bank of America cut their price objective on United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a report on Wednesday, June 11th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company cut their price objective on United Therapeutics from $314.00 to $295.00 and set an “equal weight” rating for the company in a report on Thursday, July 31st. Finally, UBS Group cut their price target on United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a report on Monday, June 30th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $379.69.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock worth $24,618,359 over the last three months. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.